Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

Sven-Eric Olsson; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Joakim Dillner; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Roger Maansson; Scott Vuocolo; Teresa M Hesley; Alfred Saah; Eliav Barr; Richard M Haupt

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

Sven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, Mauricio Hernandez-Avila, Cosette M Wheeler, Gonzalo Perez, Darron R Brown, Laura A Koutsky, Eng Hseon Tay, Patricia García, Kevin A Ault, Suzanne M Garland, Sepp Leodolter, Grace W K Tang, Daron G Ferris, Jorma Paavonen, Matti Lehtinen, Marc Steben, F Xavier BoschJoakim Dillner, Elmar A Joura, Slawomir Majewski, Nubia Muñoz, Evan R Myers, Luisa L Villa, Frank J Taddeo, Christine Roberts, Amha Tadesse, Janine Bryan, Roger Maansson, Scott Vuocolo, Teresa M Hesley, Alfred Saah, Eliav Barr, Richard M Haupt

188 Citationer (Scopus)

Abstract

In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL/SILGARD) clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these women, prophylactic administration of the vaccine was highly effective in preventing HPV 6/11/16/18-related cervical disease. Of the remaining women, 15% of had evidence of past infection with one or more vaccine HPV types (seropositive and DNA negative) at the time of enrollment. Here we present an analysis in this group of women to determine the efficacy of the HPV 6/11/16/18 vaccine against new cervical and external anogenital disease related to the same vaccine HPV type which had previously been cleared. Vaccine tolerability in this previously infected population was also assessed.

Originalsprog	Engelsk
Tidsskrift	Human Vaccines
Vol/bind	5
Udgave nummer	10
Sider (fra-til)	696-704
Antal sider	9
Status	Udgivet - 1 okt. 2009

Citationsformater

Olsson, S.-E., Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., García, P., Ault, K. A., Garland, S. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Paavonen, J., Lehtinen, M., Steben, M., ... Haupt, R. M. (2009). Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines, 5(10), 696-704.

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. / Olsson, Sven-Eric; Kjaer, Susanne K; Sigurdsson, Kristján et al.
I: Human Vaccines, Bind 5, Nr. 10, 01.10.2009, s. 696-704.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Olsson, S-E, Kjaer, SK, Sigurdsson, K, Iversen, O-E, Hernandez-Avila, M, Wheeler, CM, Perez, G, Brown, DR, Koutsky, LA, Tay, EH, García, P, Ault, KA, Garland, SM, Leodolter, S, Tang, GWK, Ferris, DG, Paavonen, J, Lehtinen, M, Steben, M, Bosch, FX, Dillner, J, Joura, EA, Majewski, S, Muñoz, N, Myers, ER, Villa, LL, Taddeo, FJ, Roberts, C, Tadesse, A, Bryan, J, Maansson, R, Vuocolo, S, Hesley, TM, Saah, A, Barr, E & Haupt, RM 2009, 'Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection', Human Vaccines, bind 5, nr. 10, s. 696-704.

@article{4dbceb3f12494734a12a6d153c574b4d,

title = "Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection",

abstract = "In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL/SILGARD) clinical program, 73% of women aged 16-26 were na{\"i}ve to all vaccine HPV types. In these women, prophylactic administration of the vaccine was highly effective in preventing HPV 6/11/16/18-related cervical disease. Of the remaining women, 15% of had evidence of past infection with one or more vaccine HPV types (seropositive and DNA negative) at the time of enrollment. Here we present an analysis in this group of women to determine the efficacy of the HPV 6/11/16/18 vaccine against new cervical and external anogenital disease related to the same vaccine HPV type which had previously been cleared. Vaccine tolerability in this previously infected population was also assessed.",

author = "Sven-Eric Olsson and Kjaer, {Susanne K} and Kristj{\'a}n Sigurdsson and Ole-Erik Iversen and Mauricio Hernandez-Avila and Wheeler, {Cosette M} and Gonzalo Perez and Brown, {Darron R} and Koutsky, {Laura A} and Tay, {Eng Hseon} and Patricia Garc{\'i}a and Ault, {Kevin A} and Garland, {Suzanne M} and Sepp Leodolter and Tang, {Grace W K} and Ferris, {Daron G} and Jorma Paavonen and Matti Lehtinen and Marc Steben and Bosch, {F Xavier} and Joakim Dillner and Joura, {Elmar A} and Slawomir Majewski and Nubia Mu{\~n}oz and Myers, {Evan R} and Villa, {Luisa L} and Taddeo, {Frank J} and Christine Roberts and Amha Tadesse and Janine Bryan and Roger Maansson and Scott Vuocolo and Hesley, {Teresa M} and Alfred Saah and Eliav Barr and Haupt, {Richard M}",

year = "2009",

month = oct,

day = "1",

language = "English",

volume = "5",

pages = "696--704",

journal = "Human Vaccines",

issn = " 1554-8619",

publisher = "Landes Bioscience",

number = "10",

}

TY - JOUR

T1 - Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

AU - Olsson, Sven-Eric

AU - Kjaer, Susanne K

AU - Sigurdsson, Kristján

AU - Iversen, Ole-Erik

AU - Hernandez-Avila, Mauricio

AU - Wheeler, Cosette M

AU - Perez, Gonzalo

AU - Brown, Darron R

AU - Koutsky, Laura A

AU - Tay, Eng Hseon

AU - García, Patricia

AU - Ault, Kevin A

AU - Garland, Suzanne M

AU - Leodolter, Sepp

AU - Tang, Grace W K

AU - Ferris, Daron G

AU - Paavonen, Jorma

AU - Lehtinen, Matti

AU - Steben, Marc

AU - Bosch, F Xavier

AU - Dillner, Joakim

AU - Joura, Elmar A

AU - Majewski, Slawomir

AU - Muñoz, Nubia

AU - Myers, Evan R

AU - Villa, Luisa L

AU - Taddeo, Frank J

AU - Roberts, Christine

AU - Tadesse, Amha

AU - Bryan, Janine

AU - Maansson, Roger

AU - Vuocolo, Scott

AU - Hesley, Teresa M

AU - Saah, Alfred

AU - Barr, Eliav

AU - Haupt, Richard M

PY - 2009/10/1

Y1 - 2009/10/1

N2 - In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL/SILGARD) clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these women, prophylactic administration of the vaccine was highly effective in preventing HPV 6/11/16/18-related cervical disease. Of the remaining women, 15% of had evidence of past infection with one or more vaccine HPV types (seropositive and DNA negative) at the time of enrollment. Here we present an analysis in this group of women to determine the efficacy of the HPV 6/11/16/18 vaccine against new cervical and external anogenital disease related to the same vaccine HPV type which had previously been cleared. Vaccine tolerability in this previously infected population was also assessed.

AB - In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL/SILGARD) clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these women, prophylactic administration of the vaccine was highly effective in preventing HPV 6/11/16/18-related cervical disease. Of the remaining women, 15% of had evidence of past infection with one or more vaccine HPV types (seropositive and DNA negative) at the time of enrollment. Here we present an analysis in this group of women to determine the efficacy of the HPV 6/11/16/18 vaccine against new cervical and external anogenital disease related to the same vaccine HPV type which had previously been cleared. Vaccine tolerability in this previously infected population was also assessed.

M3 - Journal article

C2 - 19855170

SN - 1554-8619

VL - 5

SP - 696

EP - 704

JO - Human Vaccines

JF - Human Vaccines

IS - 10

ER -

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

Abstract

Fingeraftryk

Citationsformater